The Effect of Electroacupuncture on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy)

Description

This study is a randomized controlled trial of electroacupuncture (referred to as EA) versus sham acupuncture (referred to as EA) as effective treatments for Chemotherapy-Induced Peripheral Neuropathy/CIPN pain in cancer survivors.

Conditions

Chemotherapy-induced Peripheral Neuropathy, Nerve Pain, Neuropathy, Neuropathy, Painful

Talk to us

Study Overview

On this page

Study Details

Study overview

This study is a randomized controlled trial of electroacupuncture (referred to as EA) versus sham acupuncture (referred to as EA) as effective treatments for Chemotherapy-Induced Peripheral Neuropathy/CIPN pain in cancer survivors.

A Randomized Phase III Clinical Trial of Acupuncture for Chemotherapy-induced Peripheral Neuropathy Treatment (ACT)

The Effect of Electroacupuncture on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy)

Condition
Chemotherapy-induced Peripheral Neuropathy
Intervention / Treatment

-

Contacts and Locations

Boston

Dana Farber Cancer Institute, Boston, Massachusetts, United States, 02215

Basking Ridge

Memorial Sloan Kettering Basking Ridge (Limited protocol activities), Basking Ridge, New Jersey, United States, 07920

Middletown

Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown, New Jersey, United States, 07748

Montvale

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States, 07645

New York

Memorial Sloan - Kettering Cancer Center, New York, New York, United States, 10021

Rockville Centre

Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre, New York, United States, 11553

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * English-proficient men and women aged ≥18 years
  • * Free of oncologic disease by clinical examination and history
  • * Completed neurotoxic chemotherapy such as platinum agents, taxanes, vinca alkaloids, and bortezomib at least three months prior to enrollment
  • * Diagnosis of CIPN based on symptom history, loss of deep tendon reflexes, or the presence of symmetrical stocking-glove pain, numbness, or paresthesia73
  • * Grade ≥1 sensory pain based on the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
  • * Self-reported moderate to severe CIPN pain, as defined by a score of 4 or greater on the BPI-SF average pain item over the past week
  • * On a stable regimen (no change in the past three months) if taking anti-neuropathy or other pain medications
  • * Willing to adhere to requirement that no new pain medication be taken throughout the first 12 weeks of the study period
  • * Willing to adhere to all study-related procedures, including randomization to one of the two possible acupuncture treatments
  • * Patients with a pacemaker or other electronically charged medical device
  • * Use of acupuncture for symptom management within the past 12 months

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Dana-Farber Cancer Institute,

Ting Bao, MD, PRINCIPAL_INVESTIGATOR, Dana-Farber Cancer Institute

Study Record Dates

2025-12-31